Indian Council of Medical Research, Scientist and Head of Epidemiology and Communicable Diseases Division, Dr. Samiran Panda said that the immunity produced by the Covaxin is expected to address the mutants of the virus as well.
"The vaccine that India has developed (Covaxin) presents to the immune system a wide array of antigens, so the immunity which will be produced after vaccination is expected to address the mutants as well," said Dr Samiran Panda.
On the herd immunity produced by vaccination, Panda said that Indian program has taken smart vaccination approach, rather than mass vaccination approach.
"Herd immunity produced by vaccination is a good idea but when virus mutates, immunity might not be working against it even if it is a drift," he added.
